Lytix Biopharma Overview
- Founded
- 2003
- Status
- Private
- Employees
- 14
- Latest Deal Type
- IPO
- (Cancelled)
- Latest Deal Amount
- $33.9M
- Investors
- 11
Lytix Biopharma General Information
Description
Developer of drugs designed to provide the treatment of antibiotic-resistant infections and cancer. The company's drug conducts research in the fields of synthetic peptide therapeutics and the therapies are focused on destroying bacteria and cancer cells, enabling patients to achieve an active immune system in the process.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- P.O. Box 6447
- 9294 Tromsø
- Norway
+47 77 00 00 00
Lytix Biopharma Timeline
Lytix Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. IPO | 20-Apr-2018 | $33.9M | Cancelled | Clinical Trials - Phase 1 | ||
| 12. Later Stage VC | 22-Aug-2017 | 000.00 | 0000 | 0000 | Completed | Clinical Trials - Phase 1 |
| 11. Grant | 30-Jan-2017 | 00.000 | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 10. Accelerator/Incubator | 11-Feb-2016 | 000.00 | Completed | Clinical Trials - Phase 1 | ||
| 9. Later Stage VC | 15-Dec-2015 | 00.00 | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 8. Later Stage VC | 01-Jan-2015 | 00.000 | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 7. Later Stage VC | 22-Dec-2014 | 00.000 | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 6. Grant | 07-Nov-2013 | 00.00 | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 5. Later Stage VC | 01-Jan-2013 | $15.1M | $50.2M | Completed | Clinical Trials - Phase 1 | |
| 4. Later Stage VC | 01-Jan-2011 | $8.38M | $35.1M | Completed | Clinical Trials - Phase 1 |
Lytix Biopharma Executive Team (14)
Lytix Biopharma Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Gert Munthe | Self | Board Member | 000 0000 |
| Per Sørensen | Lytix Biopharma | Board Member | 000 0000 |
Lytix Biopharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialLytix Biopharma Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Norwegian Cancer Society | Other | Minority | 000 0000 | 000000 0 | |
| Norwegian Research Council | Other | 000 0000 | 000000 0 | ||
| Oslo Cancer Cluster Incubator | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
| Care Holding | Other | Minority | 000 0000 | 000000 0 | |
| Hopen Invest | Other | Minority | 000 0000 | 000000 0 |